SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

DN401

Cat. No.:	HY-115781
CAS No.:	2135749-60-7
Molecular Formula:	$C_{13}H_9BrClN_5O_2$
Molecular Weight:	382.6
Target:	HSP
Pathway:	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

DN401 is a potent TRAP1 inhibitor with an IC_{50} of 79 nM. DN401 shows a weak inhibition of Hsp90 (IC_{50} of 698 nM). DN401 inactivates mitochondrial TRAP1 and has potent anticancer activities[1].

IC_{50} & Target

TRAP1	HSP90
79 nM (IC_{50})	698 nM (IC_{50})

In Vitro

DN401 (5-20 μM; 24 hours) has superior cancer-specific cytotoxicity but reduced cytotoxic effects in normal cells[1].
DN401 (20 μM; 6 hours) inhibits the expression of Chk1 and Akt in HeLa cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	HeLa, SK-HEP-1, T98G, H460, and PC3 cells
Concentration:	5 μM, 10 μM, 15 μM, 20 μM
Incubation Time:	24 hours
Result:	Exhibited cytotoxic activity.

Western Blot Analysis[1]

Cell Line:	HeLa cells
Concentration:	20 μM
Incubation Time:	6 hours
Result:	Inhibited the expression of Chk1 and Akt.

In Vivo

DN401 (30 mg/kg; ip; once daily; for 14 days) reduces tumor growth and increases apoptotic cell death in tumor tissues, and does not cause weight loss or histologic abnormalities[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-week-old BALB/c nu/nu male mice injected with PC3 cells[1]
Dosage:	30 mg/kg
Administration:	ip; once daily; for 14 days
Result:	Reduced tumor growth.

REFERENCES

[1]. Hye-Kyung Park, et al. Paralog Specificity Determines Subcellular Distribution, Action Mechanism, and Anticancer Activity of TRAP1 Inhibitors. J Med Chem. 2017 Sep 14;60(17):7569-7578.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA